The components themselves — what was recovered, from which sources, through what evidence chains — remain proprietary. The strategic position the corpus enables is documented in public reference. The asset itself remains held.
The VetusKodex™ corpus is described in this canonical reference at the level of its scope, civilizational reach, source-material categories, analytical capabilities, structural-architecture framework, and integration with the broader discipline of endogenic pharmacology. Three categories of specifics remain proprietary and are not disclosed in public-facing communications.
The specific compound preparations reconstructed within the corpus. The specific ingredient identities, ratio architectures, preparation methodologies, and delivery substrates documented for individual compounds. The specific historical names of formulations whose original specifications have been recovered through the translation work.
The specific primary source materials translated within the corpus. The specific historical figures, translator authorities, and scholarly works whose output underlies the corpus translations. The geographic and institutional locations of specific source materials examined in their original physical form.
The analytical methodology by which transmission corruption is identified for individual compounds and by which original specifications are recovered. The engineering pathway from classical specification to modern pharmaceutical-grade product. The cross-referencing methodology by which dispersed-source integration recovers components not preserved in any canonical lineage.
The four preceding pillars of this VetusKodex™ section document the strategic position the corpus enables: the temporal and civilizational scope of the source materials, the empirical finding that contemporary recreations operate on transmission-degraded specifications, the four canonical specification categories that constitute a classical compound preparation, the eight analytical and translation capabilities exercised in primary-source engagement, and the methodology by which the recovered specifications translate into the Foundation product line. The Foundation product portfolio is further protected by a proprietary, patent-pending estate.
What is documented publicly is the strategic position the corpus enables. What is reserved is the asset itself — the specific recovered specifications and the analytical methodology that produces them. Both dispositions are required for the corpus to function as both a canonical scientific reference and a defensible proprietary asset.
The components themselves — what was recovered, from which sources, through what evidence chains — remain proprietary.
— Daniel William Dorsey, CEO & Co-Founder · Daniel Nowak, CTO & Co-Founder · Atumnus, LLC